Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Catalyst and Wyeth Ink Agreements Worth Up To $100M

  • Catalyst Biosciences signed two agreements with Wyeth Pharmaceuticals with potential payments of up to $100 million plus royalties. The research collaboration and license agreements support discovery and preclinical development using Catalyst's Alterase™ therapeutics platform (engineered human proteases) directed at a target in metabolic disease and one in oncology.

    Wyeth will be responsible for the clinical development, manufacturing, and marketing of products developed as a result of these collaborations. The deal includes an upfront license payments, milestone payments, R&D funding, and royalties on product sales.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »